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Abstract
The Notch-3 receptor is a recognized key regulator of vascular responses and is
increasingly associated with tumorigenesis. Hypoxia-inducible factors activate
specific signaling pathways such as Notch in a number of cellular models. This
study aimed to evaluate the regulation of Notch-3 by hypoxia in prostate cancer
cells. Notch-3 gene and protein expression was established in a panel of aerobic
and hypoxic prostate cell lines in vitro, the CWR22 xenograft model and RNA
extracted from low grade (Gleason score < = 6); high grade (Gleason score > =
7); non-hypoxic (low HIF, low VEGF); hypoxic (high HIF, high VEGF) patient
FFPE specimens. NOTCH-3 was upregulated in PC3 (3-fold), 22Rv1 (4.1-fold)
and DU145 (3.8-fold) but downregulated in LnCaP (12-fold) compared to the
normal cell lines. NOTCH-3 expression was modified following hypoxic exposure
in these cells. NOTCH-3 was upregulated (2.2-fold) in higher grade and hypoxic
tumors, when compared to benign and aerobic pools. In the CWR22 xenograft
model, Notch-3 expression was restored in castrate resistant tumors. Nuclear
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exposure of cells to hypoxia but not associated with a change in expression of
HES-1. Our data further identifies Notch-3 as a potentially key hypoxic-responsive
member of the Notch pathway in prostate tumorigenesis.
Keywords: Medicine, Cell biology
1. Introduction
Notch-3 is one of the four receptors of the Notch pathway, whose interaction with
associated ligands (Jagged 1 & 2, and Delta-like homologues 1–4) regulates a
number of biological functions such as differentiation, proliferation, angiogenesis,
apoptosis and stem cell renewal [1, 2, 3, 4]. Notch-3 is emerging as a potential
marker of treatment resistance in several cancer types and was identified as a novel
exosomal protein in the DU145 prostate cancer cell line [5]. Recognized as a major
signaling pathway that is deregulated in cancer [6, 7], the Notch pathway has been
proposed to facilitate prostatic tumorigenesis, influence the outcome of anti-cancer
hormonal [8, 9] and docetaxel treatments [10] and may be particularly involved in
the development of prostate cancer in men with high body mass index [11]. As a
result Notch inhibition is being explored for the simultaneous targeting of several
cancer properties and represents an attractive novel anti-cancer therapy [12].
Activation, regulation, and degradation of the Notch signal require endosomal
trafficking of both ligands and receptors, [13, 14] which may be negatively
controlled by the Numb protein, an important cell fate determinant [15, 16].
Cleavage of the Notch receptors following ligand interaction releases the Notch
intracellular domain (NICD) to allow its translocation into the nucleus and
induction of downstream target genes expression, such as several helix-loop-helix
transcription factors named Hairy/Enhancer of split HES and HEY [17, 18]. While
accumulated evidence mostly relates to the upregulation of the Notch-1 receptor in
prostate tumors, [19, 20] expression of the Notch-3 and Notch-4 receptors in
cancer has been less commonly reported, but they appear elevated in glioblastoma,
[21] salivary adenoid cystic carcinoma, [22] breast, [23, 24] cervical [25] and
ovarian cancer [26, 27]. In prostate cancer patients, Notch-3 expression was
positively correlated to Gleason score [4]. The mechanistic significance for the
preferential expression of each Notch receptor in tumors however remains to be
elucidated.
Tumor hypoxia is a common feature of prostate tumors that is associated with
disease progression and treatment resistance [28]. Notch activity has been
associated with vascular endothelial growth factor (VEGF) [29] and hypoxia
inducible factor 1 alpha (HIF-1α) expression, [30] two well-recognized markers
of tumor hypoxia. Many oxygen-responsive genes are regulated by the hypoxia-
inducible factor-1 (HIF-1) complex. HIF-1α overexpression, evidenced by
increased immunostaining, has been reported in a variety of human cancers
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and their metastases, including prostate cancer [31, 32]. Evidence of a
relationship between the Notch-, androgen- and hypoxia-responsive pathways is
accumulating, and could be centrally controlled by the HIF-1α transcription
factor [33, 34, 35].
The Notch signaling pathway is essential to the regulation of blood vessel structure
[36, 37] and relates to the altered microvasculature and vascular function within
tumors (including those of the prostate) [38, 39]. The Notch-3 receptor is
particularly involved in the ischemic response of blood vessels [40] and has been
proposed to facilitate breast cancer stem-cell survival under hypoxic conditions
[23]. The activation of Notch-3 signaling was reported in hypoxic prostate cancer
[4]. In vitro, exposure of LnCaP prostate cancer cells to hypoxic conditions (2%
oxygen) induced Notch-3 receptor activation and compromised both proliferative
activity and migration into lipid rafts [4]. In patient biopsy specimens, Notch-3
immunostaining correlated with expression of the carbonic anhydrase IX hypoxia
marker [4].
This study expands this work. We initially examined the expression patterns of
Notch ligand and receptors in prostate specimen prior to further evaluation of the
Notch-3 receptor in prostate cancer models. We identify potential regulation of
Notch-3 by androgens in prostate cancer xenografts. We report a role of hypoxia in
the regulation of NOTCH-3 mRNA levels in vitro and in patient specimens. We
confirm modification of Notch-3 protein levels by hypoxia in additional prostate
cancer cell lines and document reduction in activation and nuclear translocation of
the Notch-3 intracellular domain under these conditions.
2. Materials and methods
2.1. In vitro models
Human prostate cancer cell lines (22Rv1, DU145, PC3, LnCaP) (ATCC, UK) were
maintained in RPMI 1640 medium (Gibco, UK) supplemented with 10% foetal calf
serum (Globepharm, UK) and 1% streptomycin-penicillin (Gibco, UK). Normal
human prostate cell lines PWR-IE and RPWE-1 were routinely maintained in
Keratinocyte SFM medium (Gibco, UK) supplemented with Bovine Pituitary
Extract, recombinant Epidermal Growth Factor and 1% streptomycin-penicillin
(Gibco, UK). Hypoxic conditions (0.5% oxygen, 48 hours) were achieved in a 1000
in vivo hypoxic chamber (BioTrace. UK).
2.2. In vivo model of castration resistance
Tissue specimens were obtained from CWR22 prostate carcinoma xenograft
prepared as described in Roe et al. [41]. Briefly, 8 mm diameter ADT-naïve
CWR22 tumor xenografts were allowed to grow to 12 mm prior to surgical
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castration. Tumor diameter was monitored. Tissue samples were collected at
baseline, when tumor diameter reached 8 mm (∼one month post castration), 4 mm
(∼four month post castration) and in relapsing tumors, when the tumor diameter
returned to 8 mm.
2.3. NOTCH-3 RT-PCR
RNA was extracted from 60–80% confluent aerobic and hypoxic cell culture flasks
or pooled CWR22 tissue samples (N = 3/pool) using Qiagen RNA extraction kit
(Qiagen, Crawley, UK). NOTCH-3 gene expression was examined using a
pre-optimized single Taqman® assay (Applied Biosystem, UK). The comparative
ΔΔCT method was used to analyze results which were normalized to β-actin
housekeeping gene expression, in three biological replicates of each cell line. The
benign PWR1E cell line was used as a reference sample to determine Notch-3
expression patterns associated with disease progression. Aerobic samples were
used as reference to determine hypoxic induction of the gene in each cell line.
Baseline tissue samples were used as reference to Notch-3 expression patterns in
our CW22R castration resistance model.
2.4. Protein extraction
Prostate cells/CW22R tissue were trypsinised, and centrifuged (3 min, 1500 rpm,
4°C). To generate whole cell lysates, the pellet was resuspended in cold RIPA lysis
buffer supplemented with a protease inhibitor cocktail (Santa Cruz, UK).
Following 10 min incubation on ice, the lysates were centrifuged at 4°C for 20
min (15,000 rpm). Separation of nuclear and cytoplasmic proteins was achieved
using NE-PERTM Nuclear and Cytoplasmic Extraction Kit (Fisher Scientific, UK)
according to manufacturer’s instruction.
2.5. Western blotting
Equal amounts of protein from the lysates were separated by electrophoresis on 6%
polyacrylamide gels and then transferred onto Hybond-C Super nitrocellulose
membrane (Amersham, UK). Western blots were probed with either rabbit
monoclonal anti-Notch-3 antibody (#ab23426, 1:250 in milk, Abcam, UK), goat
anti-NUMB (#ab4147, 1:1000 in milk, Abcam) or rabbit anti-HES1 (#ab41970,
1:1000 in BSA, Abcam). After washing, the membrane was incubated with
Horseradish peroxidase conjugated goat secondary antibody (sc-2020, 1:1000 in
BSA, Santa Cruz) or Anti-Rabbit IgG HRP Linked (#7074, 1:1000 in BSA, Cell
signaling) antibodies. Pierce Luminal kit (Pierce, UK) was used for protein
detection. Membranes were stripped prior to reprobing with either a mouse
monoclonal anti-actin (1:10000 in milk, Sigma-Aldrich, UK), rabbit anti-tubulin
(#2148S, 1:2000 in BSA, Cell Signalling), rabbit anti-Mek 1/2 (#8727, 1:1000 in
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BSA, Cell Signalling, UK) or rabbit anti-histone H3 (#4499, 1:1000 in BSA, Cell
signaling) antibodies.
2.6. Human prostate tissue specimen profiling
This study was approved by the Adelaide and Meath Hospital (AMNCH) and
St. James’s Hospital Ethics committee, Dublin, Ireland. Prostate tumors and
histologically normal adjacent formalin fixed paraffin embedded (FFPE) tissue
from patients with primary disease treated by radical prostatectomy at AMNCH
were obtained retrospectively in accordance to the approved guidelines, as
described previously [42]. All patients provided written informed consent. To
overcome the limited amount of RNA obtained from FFPE tissues, RNA samples
were pooled. Four different pools were generated: prostate cancer, high grade
prostatic intraepithelial neoplasia (HGPIN), histologically benign (HB) and benign
prostatic hyperplasia (BPH). Prostate cancer pools were further subdivided into
Gleason score ≥7 and Gleason score ≤6. Similarly, RNA was additionally
extracted from Gleason score ≤6 tumor specimens previously immunostained for
HIF-1α and VEGF 39 to generate both “aerobic” (low HIF-1α, low VEGF staining
intensity) and “hypoxic” (high HIF-1α, high VEGF staining intensity) pools. Each
pool consisted of DNase treated total RNA (100 ng), isolated from microdissected
tissue from four individual cases. cDNA (100 ng/sample) was prepared using a
RNA-to-cDNA kit (Applied Biosystem, Warrington, UK) according to
manufacturers’ instructions and loaded on microfluidic cards. A low density array
approach (Applied Biosystems, UK) was used to determine the expression of the
Notch receptors (Notch 1–4) and ligands (Jagged-1, DLL1, DLL4). The
comparative ΔΔCT method was used to analyze the results which were normalized
to Phospho-Glucose-Kinase-1 (PGK-1) housekeeping gene expression or β-actin
for experiments involving hypoxia. The BPH pool was used as a reference sample
to examine disease progression. The aerobic pool was used as a reference sample to
examine hypoxia.
2.7. Statistical analysis
All experiments were performed in triplicate. Statistical analysis was calculated
using SPSS software version 20.0. Differences in relative gene expression were
compared using student t-tests. A p-value of <0.05 was considered statistically
significant. Data are presented as Mean ± Standard Error of the Mean.
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3. Results
3.1. NOTCH-3 expression is elevated in high grade (Gleason ≥7)
prostate tumors
The gene expression levels of Notch receptors (1–4) and ligands (Jagged 1, DLL1,
DLL4) were determined in a series of pooled human BPH, HB, HGPIN, low grade
(Gleason ≤6) and high grade (Gleason ≥7) specimens (Fig. 1). The relative Ct
quantification method was used to determine the expression levels of these genes
with prostate tumorigenesis (BPH, HGPIN, low grade and higher grade tumors)
relative to BPH specimens. All Notch ligands and the NOTCH-2 receptor were
expressed in BPH specimens. JAGGED-1, DLL-1 and NOTCH-2 expression levels
were relatively stable across all pools. DLL-4 expression was significantly reduced
in HGPIN (p < 0.001) high grade tumors (p < 0.001). NOTCH-1 expression was
significantly increased in all pools (p < 0.001). NOTCH-4 was detected in HB
specimens only. NOTCH-3 expression was significantly increased in HB specimen
(p < 0.001), lost in HGPIN and detected at progressively higher levels in low
(p < 0.001) and high grade tumors (p < 0.001).
3.2. Notch-3 expression patterns in prostate cancer cells
NOTCH-3 mRNA levels were determined in a panel of prostate cancer cell lines
(22Rv1, androgen-sensitive; LnCaP, metastatic androgen-sensitive; DU145 and
PC3, metastatic, androgen-refractory) and compared to basal levels measured in a
benign prostate line (PWR1E) (Fig. 2A). In androgen-sensitive cell lines,
NOTCH-3 expression was significantly upregulated in 22Rv1 (p = 0.004) but
[(Fig._1)TD$FIG]
Fig. 1. Expression pattern of Notch ligands and receptors in human prostate tissue specimens. A low
density gene array approach was used to compare expression of genes in the Notch signalling pathway
between histologically benign, BPH, HGPIN and malignant prostate specimens (low grade (Gleason
score < = 6), high grade (Gleason score > = 7)) in pooled mRNA (N = 4 patients/pool). The 2−ΔΔCT
method was used for quantification of each sample relative to BPH control. The Log10 Rq values are
presented in each pool. N = 2, mean ± SEM. *, p < 0.05.
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strongly downregulated (12-fold) in the LnCaP metastatic line (p = 0.007).
NOTCH-3 expression was significantly upregulated in the two other
androgen-independent metastatic lines tested (DU145 (p = 0.04), PC3 (p = 0.04)).
This pattern was confirmed by western blot analysis for the full-length Notch-3
receptor in whole cell lysates (Fig. 3A). Notch-3 activation was evidenced through
the detection of the nuclear intracellular domain (N3ICD). Notch-3 expressing
22Rv1, PC3 and DU145 cells also expressed the notch regulatory NUMB protein
and the Notch-target HES-1 (Fig. 3B).
3.3. Notch-3 expression patterns in androgen independent
prostate cancer cells
Notch-3 expression was examined in an in vivo xenograft model of castration
resistance. Notch-3 gene and protein expression levels were measured at baseline,
one month and four month following castration and in relapsing tumors. A trend
towards a reduction in NOTCH-3 mRNA levels following castration was observed.
Castration-induced decrease in Notch-3 levels was confirmed by Western blot.
Detection of the receptor was reduced in long-term castrated xenografts and
restored to baseline levels at relapse (Fig. 4).
[(Fig._2)TD$FIG]
Fig. 2. NOTCH-3 expression in prostate cancer cell lines. NOTCH-3 mRNA levels were measured in a
panel of prostate cell lines. (A) NOTCH-3 Log10 Rq values in in vitro models of primary (22Rv1,
androgen-sensitive (AS)) and metastatic androgen-sensitive (LnCaP), and androgen-independent (AI)
(DU145, PC3) cell lines relative to PWRE1 benign prostate cells. (B) NOTCH-3 Log10 Rq values in
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3.4. Hypoxia prevents nuclear translocation of the Notch-3
nuclear intracellular domain
We next determined whether Notch-3 was responsive to hypoxic shock (48 hrs, 0.5%
O2).NOTCH-3 expression in hypoxic cells was measured in our panel of prostate cell
lines and compared to that of aerobic controls (Fig. 2B). NOTCH-3 was increased in
response to hypoxic exposure in DU145 (2-fold) (p = 0.04) and LnCaP (2-fold) (p =
0.04) but downregulated in 22Rv1 (15-fold) (p = 0.02) and PC3 (20-fold) (p = 0.02)
cells. These changes in gene expression correlated with up- or downregulation of the
full length Notch-3 receptor protein, as evidenced by western blotting in aerobic and
hypoxic whole cell protein lysates (Fig. 3A). Hypoxia appeared to downregulate
Notch-3 protein levels in 22Rv1 and PC3 cells, while the protein was detected as
higher levels in both LnCaP and DU145 cells. Notch-3 activation was evidenced
through the detection of the nuclear intracellular domain (N3ICD). To further
examine the regulation of Notch-3 by hypoxia, expression of N3ICDwasmeasured in
nuclear and cytoplasmic protein lysates in 22Rv1, DU145 and PC3 cells (Fig. 5A).
The N3ICDwas detected in the nucleus of aerobic cells whereas in samples collected
from hypoxic cells, amounts were below detection levels. To begin to evaluate the
potential consequences for this reduction, the expression of NUMB, RBPSUH and
HES-1 was determined. However no modifications in expression patterns in hypoxic,
compared to aerobic samples were detected (Fig. 5B).
[(Fig._3)TD$FIG]
Fig. 3. Notch-3, NUMB and HES-1 protein expression in prostate cancer cell lines. (A) Representative
immunoblot for the full length Notch-3 protein (244 kDa) and its truncated form (N3ICD (120KDa)) in
PWR1E and RWPE1 normal prostate cells and a panel of aerobic and hypoxic prostate cancer cells
(22Rv1, DU145, PC3). (B) Representative immunoblot for the NUMB and HES-1 proteins in PWR1E
and RWPE1 normal prostate cells and a panel of prostate cancer cells. (22Rv1, DU145, PC3). Tubulin
immunostaining was used as a loading control. A: aerobic, H: hypoxic (0.5% O2, 48 hrs) The full
western blots are presented in the supplementary material.
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[(Fig._4)TD$FIG]
Fig. 4. Notch-3 expression in CWR22 xenografts. (A) NOTCH-3 Log10 Rq values measured in
castrated and castration resistant relative to androgen sensitive CWR22 pooled tissue specimens. (B)
Representative immunoblot of full length Notch-3 receptor in androgen sensitive (AS), one month post
castration (ADS), 7 month post castration (ADL) and in androgen resistant relapsed tumors (CR).
Tubulin immunostaining was used as a loading control. The full western blots are presented in the
supplementary material.
[(Fig._5)TD$FIG]
Fig. 5. Loss of notch-3 intracellular domain nuclear translocation under hypoxic conditions. (A)
Representative immunoblot for the truncated Notch-3 protein (120 kDa) in the cytoplasmic and nuclear
protein fraction of 22Rv1, DU145 and PC3 cells. (B) Representative immunoblot for the NUMB,
RBPSUH and HES-1 protein in aerobic and hypoxic 22Rv1, DU145 and PC3 cells. A: aerobic, H:
hypoxia (5% O2, 48 hrs). The full western blots are presented in the supplementary material.
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3.5. NOTCH-3 mRNA levels are elevated in hypoxic tumor
specimen
To further elucidate potential role of hypoxia on NOTCH-3, expression was
determined in low grade (Gleason score ≤6) human tumor specimens, whose HIF-1α
andVEGF immunostaining intensities were previously characterized [43].“Hypoxia”
was defined as combined high HIF-1α and high VEGF staining intensities, whereas
samples staining weakly for both markers were considered “aerobic”. Relative to
benign specimens, NOTCH-3 expression was significantly reduced in the aerobic
pool (p = 0.049) and non-significantly elevated in the “hypoxic” pool (Fig. 6).
NOTCH-3 expression was significantly higher in the hypoxic, when compared to the
aerobic pools (p = 0.005).
4. Discussion
The intrinsic role of the Notch pathway in prostate tumorigenesis is increasingly
documented [35]. The tumor- and metastatic-specific expression patterns of Notch
family members have predominantly identified the Notch-1 receptor as a key
marker of Notch signaling deregulation in prostate cancer. Despite evidence for its
elevated expression in tumors [6, 19, 20], diminished expression of its cleaved
form and its downstream effector HEY-1 was reported in adenocarcinoma foci
when compared with benign tissues [44]. The mechanistic basis for this loss
remains unexplained, but it correlates with loss of phosphatase and tensin homolog
gene (PTEN) expression [44] and calcium/calmodulin-dependent kinase II
overexpression [45]. Highly involved in tumor vasculogenesis [46], DLL-4
expression is low in prostate tissue [47].
Along with Notch 2 and Notch 4, the Notch 3 receptor has been less extensively
studied than Notch 1. Despite previous report of undetectable expression of Notch
3 and Notch 4 in PC3 cells, [19] our examination of the mRNA levels of Notch
receptors and ligand identified significant upregulation of Notch-1 and Notch-3
[(Fig._6)TD$FIG]
Fig. 6. Notch-3 expression in hypoxic prostate cancer. NOTCH-3 Log10 Rq values in pooled mRNA
samples from prostate cancer biopsies associated with low (“aerobic”) and high (“hypoxic”) HIF and
VEGF immunostaining. N = 2, mean ± SEM. *, p < 0.05.
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and downregulation of DLL4 expression in prostate cancer, when compared to
BPH patient specimens. Similarly. Danza et al. identified a significant positive
correlation between Notch-3 immunostaining intensity and Gleason grade, with a
higher frequency of Notch-3 nuclear staining in high grade tumours [4].
Our study identifies that Notch-3 mRNA levels and protein expression are elevated
in a panel of prostate cancer cell lines (22Rv1, DU145 and PC3 cells), when
compared to the PWR1E normal prostate cell lines. Notch-3 was downregulated at
both mRNA and protein levels in the metastatic LnCaP cell line, consistent with
the reported increased Notch-3 expression in DU145 and PC3 cells compared to
LnCaP [4]. The same tumor specific pattern of expression was present when the
Numb protein was examined. The intricate relationship between Notch and Numb
is poorly reported in prostate cancer, but is likely a key factor to prostate
tumorigenesis [48]. The presence of Notch-3 and Numb did not correlate with
detection or absence of the Notch-target protein HES-1. While this suggests that
HES-1 may not be regulated by Notch-3 in these cells, examination of the Notch
pathway in the TRAMP mouse model identified a significant functional role of the
Jagged1-2/Notch3/Hey1 axis in prostate tumorigenesis [47].
Comparison of the levels of Notch-3 expression in these three metastatic cell lines
additionally suggests potential involvement of Notch-3 in the transition from
androgen-sensitive (LnCaP) to androgen-resistant state (DU145 and PC3 cells).
This hypothesis was supported by the observed trend toward initial reduction in
Notch-3 mRNA and protein levels following castration of CWR22 xenografts and
restoration of expression with the emergence of a castration resistant relapsing
tumor. A cross-talk between Notch and androgen signaling has been proposed
though Jagged1 overexpression [49], sequestration of Hey-1 in the cytoplasm of
prostate cancer cells [50, 51] and numb upregulation [52]. Further evaluation of the
inter-relationship between androgen signaling and Notch-3 is warranted.
A number of parallels exist between the cellular behavior of notch-activated and
hypoxic prostate cancer cells [35], but direct evidence of this cross talk is scarce.
Reports of the hypoxia responsiveness of the Notch pathway consistently highlight
the Notch-3 receptor as a key member of this response [4, 53, 54]. The regulation
of the Notch-3 receptor was reported in hypoxic LnCaP cells and correlated to
carbonic anhydrase IX staining intensity in prostate cancer specimen [4]. Notch-3
expression was preserved and regulated cell proliferation in LnCaP cells
chronically exposed to 2% oxygenation levels [4]. Our results strengthen evidence
for a role of Notch-3 in hypoxic prostate cancer. We confirm modification of
Notch-3 expression and activity under 0.5% oxygenation in 22Rv1, DU145, PC3 in
addition to LnCaP cells. This induction did not correlate with a modification in the
level of Numb or RBPSUH protein expression levels. At this low level of oxygen,
examination of the cytoplasmic and nuclear protein fraction identified loss of the
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Notch-3 intracellular domain in the nuclear and cytoplasmic fraction of hypoxic
22Rv1, DU145 and PC3 cells. Notch-3 nuclear activity was increased in LnCaP
cells chronically exposed to 2% oxygenation levels [4]. Our results suggest possible
dependence of Notch-3 regulation with oxygen levels. At very low oxygen levels,
hypoxia appears to either inhibit cleavage of the receptor in these cells or prevent
ligand-receptor interaction. Gamma-secretase activity seems increased by (1%)
hypoxia [3] in a possibly HIF-1 α dependent process [3], whereas at 2% oxygen,
mRNA and protein expression levels of Notch ligands (Jagged-1, Jagged-2, DLL1
and DLL-4) were significantly reduced in PC3, DU145 and LnCaP cells [54].
Analysis of NOTCH-3 mRNA levels in patient specimens confirmed previous
reports of a tumour-specific pattern that correlates with the degree of malignancy
and hypoxia [4, 55]. The identification of elevated NOTCH-3 in specimen defined
as hypoxic through analysis of alternate hypoxia markers (HIF-1α and VEGF) than
previously used (carbonic anhydrase IX) further support the need to evaluate
Notch-3 in hypoxic prostate tumours. In light of the reported increased nuclear
localization of Notch-3 in high grade tumours [4], evaluation of the clinical
relevance of the cytoplasmic and nuclear localization of this receptor is particularly
required.
In conclusion, this study strengthens previous evidence for a role for Notch-3 in the
regulation of prostate cancer cells under hypoxic conditions with potential
implications for Notch-targeted therapies. Further evaluation of activation
mechanisms of the Notch-3 receptor and characterization of its target genes are
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